Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gastrointestinal stromal tumours.

E M Connolly1, E Gaffney, J V Reynolds

  • 1Department of Surgery, St James Hospital and Trinity College Dublin, Dublin 8, Ireland.

The British Journal of Surgery
|September 30, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A proposed framework of strategies to overcome challenges to surgical quality assurance in oncology trials (SQA-Onc.).

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2025
Same author

Oesophagectomy in End-Stage Achalasia.

Irish medical journal·2024
Same author

Nutrient Intakes and Gastrointestinal Symptoms Among Esophagogastric Cancer Survivors up to 5 Years Post-Surgery.

Nutrition and cancer·2024
Same author

Defining the role of neutrophils in the lung during infection: Implications for tuberculosis disease.

Frontiers in immunology·2022
Same author

Organ preservation in the multimodality approach to locally advanced oesophageal cancer: festina lente.

The British journal of surgery·2021
Same author

Patient-reported outcomes after oesophagectomy in the multicentre LASER study.

The British journal of surgery·2021

Gastrointestinal stromal tumours (GISTs) are common mesenchymal tumours. Imatinib is the first effective therapy for advanced GISTs, showing significant patient response and reduced tumour metabolism, though further trials are needed.

Area of Science:

  • Gastroenterology
  • Oncology
  • Molecular Biology

Background:

  • Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumors of the GI tract.
  • GISTs express KIT, a growth factor receptor with tyrosine kinase activity.
  • KIT mutations drive GIST proliferation and apoptosis resistance, rendering them chemotherapy-resistant.

Purpose of the Study:

  • To review the literature on gastrointestinal tumours, GISTs, KIT, and imatinib.
  • To evaluate the efficacy of imatinib as a therapeutic agent for advanced GISTs.

Main Methods:

  • A Medline literature search was conducted.
  • Articles related to gastrointestinal tumours, GISTs, KIT, and imatinib were identified.

Main Results:

Related Experiment Videos

  • Imatinib is the first effective systemic therapy for metastatic and locally irresectable GISTs.
  • Phase II trials show over 50% of patients respond to imatinib within months, with 12% experiencing progression.
  • Positron emission tomography demonstrates reduced [(18)F]fluoro-2-deoxy-D-glucose uptake after imatinib initiation.

Conclusions:

  • Imatinib significantly improves outcomes for patients with advanced GISTs.
  • The 5-year survival rate after resection is ~50%; median survival for metastatic GIST is ~20 months.
  • Further large-scale clinical trials are necessary to determine optimal imatinib treatment duration and its role in adjuvant/neoadjuvant settings.